510(k) Report

De Novo · Granted

Granted

B.R.A.H.M.S PCT sensitive KRYPTOR

DEN150009De NovoGranted Feb 20, 2016353-day reviewClass II21 CFR 866.3215

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Brahms GmbH · PMT Device To Detect And Measure Procalcitonin (Pct) In Human Clinical Specimens

Granted on Feb 20, 2016 as a new device type through De Novo after a 353-day review. 27 later devices descend from it.

Decided
Feb 20, 2016
Review
353 days
Class
Class II
Product code
PMT
Recalls
None

27 later devices descend from it, 5 citing it directly.

Descendants, by year cleared 2017: 5 descendants cleared2016: 2 descendants cleared2018: 3 descendants cleared2021: 2 descendants cleared2020: 3 descendants cleared2022: 3 descendants cleared2019: 2 descendants cleared2025: 3 descendants cleared2023: 3 descendants cleared2024: 1 descendant cleared201620182020202220242026
  1. This deviceDEN150009 B.R.A.H.M.S PCT sensitive KRYPTORBrahms GmbH · 2016
  2. Descendant · cites it directly · 22 of its ownK160911 Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2016
  3. Descendant · 2 generations on · 21 of its ownK162827 Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2017
  4. Descendant · cites it directly · 7 of its ownK171338 B R A H M S PCT sensitive KRYPTORBrahms GmbH · 2017
  5. Descendant · 3 generations on · 3 of its ownK210254 MeMed BVMeMed Diagnostics, Ltd. · 2021
  6. Descendant · 3 generations on · 2 of its ownK220991 IntelliSep testCytovale, Inc. · 2022

Showing 5 of 27 descendants. See all descendants

Descendants cleared per year

2016: 22017: 52018: 32019: 22020: 32021: 22022: 32023: 32024: 12025: 3
2016high 5 (2017) · low 0 (2026)2026

Most influential descendants

Showing 5 of 27 · See all
  • K160911Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2016 · cites it directly22descendants
  • K162827Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc. · 2017 · 2 generations on21descendants
  • K171338B R A H M S PCT sensitive KRYPTORBrahms GmbH · 2017 · cites it directly7descendants
  • K210254MeMed BVMeMed Diagnostics, Ltd. · 2021 · 3 generations on3descendants
  • K220991IntelliSep testCytovale, Inc. · 2022 · 3 generations on2descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)DEN150009B.R.A.H.M.S PCT sensitive KRYPTORBrahms GmbH2016—
+1K160911Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc.2016—
+2K162827Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc.2017—
+1K171338B R A H M S PCT sensitive KRYPTORBrahms GmbH2017—
+3K210254MeMed BVMeMed Diagnostics, Ltd.2021—
+3K220991IntelliSep testCytovale, Inc.2022—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201620
201750
201830
201920
202030
202120
202230
202330
202410
202530
FIG. 1 — Lineage of DEN150009, 2016–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA De Novo database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PMT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PMT device

  1. #1 K200236 VITROS BRAHMS PCT Reagent Pack and Calibratorsscore -0.2 · 4 generations · no Class I recall
Get a 510(k) Report

Does it have a predicate?

De Novo decisions do not claim a predicate device.

What descends from it? (27)

See all 27

5 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K160911Vidas B.R.a.H.M.S. PCT (PCT)bioMerieux, Inc.201622
K171338B R A H M S PCT sensitive KRYPTORBrahms GmbH20177
K163260SeptiCyte LABImmunexpress, Inc.20172
K181002Atellica IM BRAHMS Procalcitonin (PCT)Siemens Healthcare Diagnostics, Inc.20180
K160729Elecys BRAHMS PCT, Elecys BRAHMS PCT CalCheck 5Roche Diagnostics20160

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K160911 (bioMerieux, Inc., 2016) has gone furthest, with 22 descendants of its own.

How does its category compare?

All PMT devices

PMT Device To Detect And Measure Procalcitonin (Pct) In Human Clinical Specimens: FDA decisions, review times, recalls and adverse event reports over 20 years. 2016, this device’s year, is highlighted.

FDA decisions per year · PMT

1in 2020

2016: 32018: 12020: 1
2007high 3 (2016) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PMT

Too few PMT 510(k)s in any year since 2007 to give a median.

Recalls per year · PMT

No recall names PMT since 2007.

Adverse event reports per year · PMT

1in 2025

2017: 42018: 32019: 12020: 12023: 22024: 12025: 1
2007high 4 (2017) · low 0 (2007)2025

MAUDE reports naming product code PMT, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20163—00
20170—04
20181—03
20190—01
20201—01
20210—00
20220—00
20230—02
20240—01
20250—01
20260—0—

What is it indicated for?

The B· R· A· H· M· S PCT sensitive KRYPTOR is an immunofluorescent assay using Time-Resolved Amplified Cryptate Emission (TRACE) technology to determine the concentration of PCT (procalcitonin) in human serum and EDTA or heparin plasma. The B· R· A· H· M· S PCT sensitive KRYPTOR is intended to be performed on the B· R· A· H· M· S KRYPTOR analyzer family. The B· R A- H· M· S PCT sensitive KRYPTOR is intended for use in conjunction with other laboratory…

Read the full statement (411 words)

The B· R· A· H· M· S PCT sensitive KRYPTOR is an immunofluorescent assay using Time-Resolved Amplified Cryptate Emission (TRACE) technology to determine the concentration of PCT (procalcitonin) in human serum and EDTA or heparin plasma.

The B· R· A· H· M· S PCT sensitive KRYPTOR is intended to be performed on the B· R· A· H· M· S KRYPTOR analyzer family.

The B· R A- H· M· S PCT sensitive KRYPTOR is intended for use in conjunction with other laboratory fmdings and clinical assessments to aid in the risk assessment of critically ill patients on their first day of Intensive Care Unit (ICU) admission for progression to severe sepsis and septic shock.

The B· R· A- H- M· S PCT sensitive KRYPTOR is also intended for use to determine the change in PCT level over time as an aid in assessing the cumulative 28-day risk of all-cause mortality in conjunction with other laboratory fmdings and clinical assessments for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission.

Procalcitonin (PCT) is a biomarker associated with the inflammatory response to bacterial infection that aids in the risk assessment of critically ill patients on their first day of Intensive Care Unit (ICU) admission for progression to severe sepsis and septic shock. The percent change in PCT level over time also aids in the prediction of cumulative 28-day mortality in patients with severe sepsis and septic shock.

PCT level on the first day of ICU admission above 2.0 Jlg/L is associated with a higher risk for progression to severe sepsis and/or septic shock than a PCT level below 0.5 Jlg/L.

A PCT level that declines::; 80% from the day that severe sepsis or septic shock was clinically diagnosed (Day 0) to four days after clinical diagnosis (Day 4) is associated with higher cumulative 28-day risk of all-cause mortality than a decline > 80%.

The combination of the PCT level (:'0 2.0 ug!L or> 2.0 Jlg/L) at initial diagnosis of severe sepsis or septic shock with the patient's clinical course and the change in PCT level over time until Day 4 provides important additional information about the mortality risk.

The PCT level on Day I (the day after severe sepsis or septic shock is first clinically diagnosed) can be used to calculate the percent change in PCT level at Day 4 if the Day 0 measurement is unavailable.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “DEN150009: B.R.A.H.M.S PCT sensitive KRYPTOR.” Lineage record from FDA De Novo data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/DEN150009

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026